logo

Regenxbio Inc (RGNX)



Trade RGNX now with
  Date
  Headline
10/4/2022 9:13:34 AM Wedbush Is Lowering Regenxbio Inc (RGNX) FY23 Rev. Estimate To 139.3 M From 168.4 M
10/4/2022 9:13:03 AM Wedbush Is Lowering Regenxbio Inc (RGNX) Q4 23 Rev. Estimate To 35.1 M From 42.4 M
10/4/2022 9:12:39 AM Wedbush Is Lowering Regenxbio Inc (RGNX) Q3 23 Rev. Estimate To 34.9 M From 42.2 M
10/4/2022 9:12:20 AM Wedbush Is Lowering Regenxbio Inc (RGNX) Q2 23 Rev. Estimate To 34.7 M From 42.0 M
10/4/2022 9:11:55 AM Wedbush Is Cutting Regenxbio Inc (RGNX) Q1 23 Rev. Estimate To 34.6 M From 41.8 M
10/4/2022 9:10:38 AM Wedbush Is Lowering Regenxbio Inc (RGNX) FY23 Estimate To -6.18 From -5.83
10/4/2022 9:10:10 AM Wedbush Is Cutting Regenxbio Inc (RGNX) Q4 23 Estimate To -1.51 From -1.42
10/4/2022 9:09:36 AM Wedbush Is Lowering Regenxbio Inc (RGNX) Q3 23 Estimate To -1.48 From -1.39
10/4/2022 9:09:15 AM Wedbush Is Lowering Regenxbio Inc (RGNX) Q2 23 Estimate To -1.59 From -1.50
10/4/2022 9:08:56 AM Wedbush Is Cutting Regenxbio Inc (RGNX) Q1 23 Estimate To -1.61 From -1.52
10/4/2022 9:07:47 AM Wedbush Reiterates Regenxbio Inc (RGNX) At Neutral With $28 Down From $32 Price Target
10/3/2022 7:06:06 AM REGENXBIO Announces Additional Positive Interim Data From Trials Of RGX-314 For The Treatment Of Wet AMD
8/31/2022 7:14:52 AM REGENXBIO Presents Addl Positive Interim Data From Phase I/II/III Trial Of RGX-121 For Treatment Of MPS II
7/8/2022 7:06:39 AM REGENXBIO Completes Enrollment In Cohort 5 Of Phase II AAVIATE Trial
2/10/2022 5:01:53 PM Wedbush Reiterates Regenxbio Inc (RGNX) At Neutral With $29 Price Target
1/6/2022 7:15:17 AM REGENXBIO Announces FDA Clearance Of IND For Clinical Trial Of RGX-202